Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
6(25%)
Results Posted
17%(1 trials)
Terminated
2(8%)

Phase Distribution

Ph phase_2
8
33%
Ph phase_4
1
4%
Ph phase_1
5
21%
Ph phase_3
3
13%
Ph not_applicable
2
8%

Phase Distribution

5

Early Stage

8

Mid Stage

4

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
5(26.3%)
Phase 2Efficacy & side effects
8(42.1%)
Phase 3Large-scale testing
3(15.8%)
Phase 4Post-market surveillance
1(5.3%)
N/ANon-phased studies
2(10.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

6

trials recruiting

Total Trials

24

all time

Status Distribution
Active(6)
Completed(6)
Terminated(4)
Other(8)

Detailed Status

unknown8
Completed6
Active, not recruiting4
Withdrawn2
Terminated2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
24
Active
6
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (26.3%)
Phase 28 (42.1%)
Phase 33 (15.8%)
Phase 41 (5.3%)
N/A2 (10.5%)

Trials by Status

unknown833%
withdrawn28%
completed625%
terminated28%
active_not_recruiting417%
recruiting28%

Recent Activity

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT02937272Phase 1

A Study of LY3200882 in Participants With Solid Tumors

Active Not Recruiting
NCT06546267

Advanced Radiotherapy (ART) in Prostate Cancer (PROST-ART)

Recruiting
NCT02753790Not Applicable

Whole Brain Radiation Using IMRT for Patients With Brain Metastases

Completed
NCT06806683

Predictive Tools in Head and Neck Cancer Patients Undergoing Radiotherapy

Active Not Recruiting
NCT04895345Phase 2

A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma

Completed
NCT03241537Phase 3

COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer

Active Not Recruiting
NCT05229315Phase 2

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

Unknown
NCT05340491Phase 3

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Recruiting
NCT03669432Not Applicable

To Study the Impact of Radiation Treatment After Surgery in Patient With Locally Advanced Thyroid Cancer.

Active Not Recruiting
NCT02864849Phase 2

Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer

Completed
NCT02860234

Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment

Completed
NCT02201355Phase 1

Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck

Terminated
NCT04405206

Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer

Unknown
NCT03196843Phase 4

Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC.

Unknown
NCT04340401Phase 2

Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen

Unknown
NCT03068936Phase 3

IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma

Unknown
NCT00593866Phase 1

Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer

Completed
NCT02149602

A Phase II Study of Parotid-gland Sparing IMRT in Patients With Midline Tumour of the Head and Neck

Completed
NCT02116231Phase 2

The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of Stage II Nasopharyngeal Carcinoma

Unknown
NCT01185145Phase 2

Accelerated Partial Breast Radiotherapy With Either Mammosite or Intensity Modulated Radiotherapy

Unknown

Drug Details

Intervention Type
RADIATION
Total Trials
24